{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:21Z","timestamp":1792887801451,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13760-022-02028-6","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T13:05:41Z","timestamp":1658408741000},"page":"1735-1745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-0063","authenticated-orcid":false,"given":"Maria","family":"Gavriilaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Papaliagkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Stamperna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Moschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Notas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Papagiannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianthi","family":"Arnaoutoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios K.","family":"Kimiskidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"issue":"1","key":"2028_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1):155\u2013165. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3","journal-title":"Cell"},{"issue":"5\u20136","key":"2028_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/s0960-8966(06)80015-5","volume":"2","author":"TL Munsat","year":"1992","unstructured":"Munsat TL, Davies KE (1992) International SMA consortium meeting (26-28 June 1992, Bonn, Germany). Neuromuscul Disord 2(5\u20136):423\u2013428. https:\/\/doi.org\/10.1016\/s0960-8966(06)80015-5","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2028_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M et al (2018) Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol 25(3):512\u2013518. https:\/\/doi.org\/10.1111\/ene.13534","journal-title":"Eur J Neurol"},{"issue":"18","key":"2028_CR4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377(18):1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"issue":"15","key":"2028_CR5","first-page":"1","volume":"92","author":"EBG Mercuri","year":"2019","unstructured":"Mercuri EBG, Kirschner J, Servais L, Goemans N, Pera MC, Buchbjerg J, Yeung WY, Kletzl H, Gerber M, Czech C, Cleary Y, Gorni K, Khwaja O (2019) Update from sunfish part 1: safety, tolerability and PK\/PD from the dose-finding study, including exploratory efficacy data in patients with type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916). Neurology 92(15):1","journal-title":"Neurology"},{"issue":"18","key":"2028_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"key":"2028_CR7","doi-asserted-by":"publisher","DOI":"10.1159\/000519831","author":"V Papaliagkas","year":"2021","unstructured":"Papaliagkas V, Foroglou N, Toulios P et al (2021) Intrathecal administration of nusinersen using the Ommaya Reservoir in an adult with 5q-related spinal muscular atrophy type 1 and severe spinal deformity. Case Rep Neurol. https:\/\/doi.org\/10.1159\/000519831","journal-title":"Case Rep Neurol"},{"key":"2028_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01200-3","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V et al (2022) Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neurotherapeutics. https:\/\/doi.org\/10.1007\/s13311-022-01200-3","journal-title":"Neurotherapeutics"},{"key":"2028_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.12.005","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V et al (2022) Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neuromuscul Disord. https:\/\/doi.org\/10.1016\/j.nmd.2021.12.005","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"2028_CR10","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, O\u2019Hagen JM, McDermott MP et al (2011) Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III. J Child Neurol 26(12):1499\u20131507. https:\/\/doi.org\/10.1177\/0883073811420294","journal-title":"J Child Neurol"},{"issue":"6","key":"2028_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J et al (2017) Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve 55(6):869\u2013874. https:\/\/doi.org\/10.1002\/mus.25430","journal-title":"Muscle Nerve"},{"key":"2028_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"2","key":"2028_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S et al (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23(2):60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid Based Med"},{"issue":"8","key":"2028_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/ACM.0000000000000786","volume":"90","author":"DA Cook","year":"2015","unstructured":"Cook DA, Reed DA (2015) Appraising the quality of medical education research methods: the Medical Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education. Acad Med 90(8):1067\u20131076. https:\/\/doi.org\/10.1097\/ACM.0000000000000786","journal-title":"Acad Med"},{"key":"2028_CR15","doi-asserted-by":"publisher","first-page":"650532","DOI":"10.3389\/fneur.2021.650532","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh B, Severyn S, Zhao S et al (2021) Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy. Front Neurol 12:650532. https:\/\/doi.org\/10.3389\/fneur.2021.650532","journal-title":"Front Neurol"},{"issue":"15","key":"2028_CR16","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1212\/WNL.94.15_supplement.4725","volume":"94","author":"C Quinn","year":"2020","unstructured":"Quinn C, Fadda G, McMillan C et al (2020) Effect of Nusinsersen in an Adult SMA Cohort: CSF biomarkers and RULM (4725). Neurology 94(15):4725","journal-title":"Neurology"},{"issue":"5","key":"2028_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/acn3.51340","volume":"8","author":"M Freigang","year":"2021","unstructured":"Freigang M, Wurster CD, Hagenacker T et al (2021) Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol 8(5):1049\u20131063. https:\/\/doi.org\/10.1002\/acn3.51340","journal-title":"Ann Clin Transl Neurol"},{"key":"2028_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10569-8","author":"B Stolte","year":"2021","unstructured":"Stolte B, Nonnemacher M, Kizina K et al (2021) Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters. J Neurol. https:\/\/doi.org\/10.1007\/s00415-021-10569-8","journal-title":"J Neurol"},{"key":"2028_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419846058","author":"CD Wurster","year":"2019","unstructured":"Wurster CD, G\u00fcnther R, Steinacker P et al (2019) Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/1756286419846058","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"2028_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00415-019-09547-y","volume":"267","author":"CD Wurster","year":"2020","unstructured":"Wurster CD, Steinacker P, G\u00fcnther R et al (2020) Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. J Neurol 267(1):36\u201344. https:\/\/doi.org\/10.1007\/s00415-019-09547-y","journal-title":"J Neurol"},{"issue":"5","key":"2028_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jnc.14953","volume":"153","author":"T Kessler","year":"2020","unstructured":"Kessler T, Latzer P, Schmid D et al (2020) Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy. J Neurochem 153(5):650\u2013661. https:\/\/doi.org\/10.1111\/jnc.14953","journal-title":"J Neurochem"},{"key":"2028_CR22","first-page":"870","volume":"27","author":"G Milella","year":"2020","unstructured":"Milella G, Scaglione G, Fraddosio A et al (2020) Role of routine cerebrospinal fluid (CSF) and serum parameters in adult 5q- SMA type 2\/3 treated with nusinersen: a prospective observational study. Eur J Neurol 27:870","journal-title":"Eur J Neurol"},{"issue":"6","key":"2028_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/mus.27212","volume":"63","author":"A Introna","year":"2021","unstructured":"Introna A, Milella G, D\u2019Errico E et al (2021) Is cerebrospinal fluid amyloid-beta42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients? Muscle Nerve 63(6):905\u2013909. https:\/\/doi.org\/10.1002\/mus.27212","journal-title":"Muscle Nerve"},{"issue":"5","key":"2028_CR24","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1111\/jcmm.14939","volume":"24","author":"I Faravelli","year":"2020","unstructured":"Faravelli I, Meneri M, Saccomanno D et al (2020) Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients. J Cell Mol Medicine 24(5):3034\u20133039. https:\/\/doi.org\/10.1111\/jcmm.14939","journal-title":"J Cell Mol Medicine"},{"key":"2028_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215397","author":"A Totzeck","year":"2019","unstructured":"Totzeck A, Stolte B, Kizina K et al (2019) Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20215397","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2028_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S et al (2019) Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study. J Neuromuscul Dis 6(4):453\u2013465. https:\/\/doi.org\/10.3233\/JND-190416","journal-title":"J Neuromuscul Dis"},{"key":"2028_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11030296","author":"LH Muschen","year":"2021","unstructured":"Muschen LH, Osmanovic A, Binz C et al (2021) Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci11030296","journal-title":"Brain Sci"},{"key":"2028_CR28","doi-asserted-by":"publisher","first-page":"650535","DOI":"10.3389\/fneur.2021.650535","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh B, Severyn S, Zhao S et al (2021) Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA. Front Neurol 12:650535. https:\/\/doi.org\/10.3389\/fneur.2021.650535","journal-title":"Front Neurol"},{"issue":"1-2","key":"2028_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.cccn.2004.02.007","volume":"344","author":"W Junge","year":"2004","unstructured":"Junge W, Wilke B, Halabi A et al (2004) Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 344(1\u20132):137\u2013148. https:\/\/doi.org\/10.1016\/j.cccn.2004.02.007","journal-title":"Clin Chim Acta"},{"key":"2028_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jflm.2018.02.016","volume":"55","author":"M Sieber","year":"2018","unstructured":"Sieber M, Dressler J, Franke H et al (2018) Post-mortem biochemistry of NSE and S100B: a supplemental tool for detecting a lethal traumatic brain injury? J Forensic Leg Med 55:65\u201373. https:\/\/doi.org\/10.1016\/j.jflm.2018.02.016","journal-title":"J Forensic Leg Med"},{"issue":"2","key":"2028_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000098441","volume":"28","author":"P Stern","year":"2007","unstructured":"Stern P, Bartos V, Uhrova J et al (2007) Performance characteristics of seven neuron-specific enolase assays. Tumour Biol 28(2):84\u201392. https:\/\/doi.org\/10.1159\/000098441","journal-title":"Tumour Biol"},{"issue":"4","key":"2028_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1136\/jnnp-2017-316605","volume":"89","author":"M De Schaepdryver","year":"2018","unstructured":"De Schaepdryver M, Jeromin A, Gille B et al (2018) Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 89(4):367\u2013373. https:\/\/doi.org\/10.1136\/jnnp-2017-316605","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2028_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG et al (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28(6):595\u2013599. https:\/\/doi.org\/10.1038\/nbt.1641","journal-title":"Nat Biotechnol"},{"issue":"9","key":"2028_CR34","doi-asserted-by":"publisher","first-page":"e921","DOI":"10.1212\/WNL.0000000000008762","volume":"94","author":"CRR Alves","year":"2020","unstructured":"Alves CRR, Zhang R, Johnstone AJ et al (2020) Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy. Neurology 94(9):e921\u2013e931. https:\/\/doi.org\/10.1212\/WNL.0000000000008762","journal-title":"Neurology"},{"issue":"3","key":"2028_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000007926","volume":"39","author":"S Rudnik-Schoneborn","year":"1998","unstructured":"Rudnik-Schoneborn S, Lutzenrath S, Borkowska J et al (1998) Analysis of creatine kinase activity in 504 patients with proximal spinal muscular atrophy types I-III from the point of view of progression and severity. Eur Neurol 39(3):154\u2013162. https:\/\/doi.org\/10.1159\/000007926","journal-title":"Eur Neurol"},{"issue":"1","key":"2028_CR36","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1212\/WNL.0000000000009559","volume":"95","author":"M Benatar","year":"2020","unstructured":"Benatar M, Zhang L, Wang L et al (2020) Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95(1):e59. https:\/\/doi.org\/10.1212\/WNL.0000000000009559","journal-title":"Neurology"},{"issue":"5","key":"2028_CR37","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","volume":"6","author":"BT Darras","year":"2019","unstructured":"Darras BT, Crawford TO, Finkel RS et al (2019) Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 6(5):932\u2013944. https:\/\/doi.org\/10.1002\/acn3.779","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"2028_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","volume":"72","author":"CL Sutphen","year":"2015","unstructured":"Sutphen CL, Jasielec MS, Shah AR et al (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72(9):1029\u20131042. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1285","journal-title":"JAMA Neurol"},{"issue":"1","key":"2028_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/1521-1878(200101)23:1<24::AID-BIES1004>3.0.CO;2-H","volume":"23","author":"C Perrone Capano","year":"2001","unstructured":"Perrone Capano C, Pernas-Alonso R, di Porzio U (2001) Neurofilament homeostasis and motoneurone degeneration. BioEssays 23(1):24\u201333. https:\/\/doi.org\/10.1002\/1521-1878(200101)23:1%3c24::AID-BIES1004%3e3.0.CO;2-H","journal-title":"BioEssays"},{"key":"2028_CR40","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3389\/fneur.2018.01167","volume":"9","author":"K Poesen","year":"2018","unstructured":"Poesen K, Van Damme P (2018) Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol 9:1167. https:\/\/doi.org\/10.3389\/fneur.2018.01167","journal-title":"Front Neurol"},{"issue":"1","key":"2028_CR41","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1212\/WNL.0000000000004761","volume":"90","author":"E Feneberg","year":"2018","unstructured":"Feneberg E, Oeckl P, Steinacker P et al (2018) Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 90(1):e22\u2013e30. https:\/\/doi.org\/10.1212\/WNL.0000000000004761","journal-title":"Neurology"},{"key":"2028_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jprot.2015.01.017","volume":"119","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Guo Z, Zou L et al (2015) A comprehensive map and functional annotation of the normal human cerebrospinal fluid proteome. J Proteom 119:90\u201399. https:\/\/doi.org\/10.1016\/j.jprot.2015.01.017","journal-title":"J Proteom"},{"issue":"5","key":"2028_CR43","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","volume":"57","author":"KJ Swoboda","year":"2005","unstructured":"Swoboda KJ, Prior TW, Scott CB et al (2005) Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 57(5):704\u2013712. https:\/\/doi.org\/10.1002\/ana.20473","journal-title":"Ann Neurol"},{"issue":"2","key":"2028_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ene.14587","volume":"28","author":"PVS Souza","year":"2021","unstructured":"Souza PVS, Pinto W, Ricarte A et al (2021) Clinical and radiological profile of patients with spinal muscular atrophy type 4. Eur J Neurol 28(2):609\u2013619. https:\/\/doi.org\/10.1111\/ene.14587","journal-title":"Eur J Neurol"},{"key":"2028_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10332-5","author":"G Querin","year":"2021","unstructured":"Querin G, Lenglet T, Debs R et al (2021) Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10332-5","journal-title":"J Neurol"},{"issue":"2","key":"2028_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","volume":"23","author":"WC Weng","year":"2021","unstructured":"Weng WC, Hsu YK, Chang FM et al (2021) CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening. Genet Med 23(2):415\u2013420. https:\/\/doi.org\/10.1038\/s41436-020-00987-w","journal-title":"Genet Med"},{"key":"2028_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324254","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D, D\u2019Silva A, Howells J et al (2020) Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2020-324254","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"2028_CR48","first-page":"464","volume":"19","author":"MMM Gavriilaki","year":"2021","unstructured":"Gavriilaki MMM, Papaliagkas V, Notas K, Chatzikyriakou E, Zafeiridou G, Papagiannopoulos S, Arnaoutoglou M, Kimiskidis V (2021) Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Eur J Neurol 19(2):464\u2013475","journal-title":"Eur J Neurol"},{"key":"2028_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110341","author":"M Gavriilaki","year":"2020","unstructured":"Gavriilaki M, Kimiskidis VK, Gavriilaki E (2020) Precision medicine in neurology: the inspirational paradigm of complement therapeutics. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph13110341","journal-title":"Pharmaceuticals"},{"issue":"6","key":"2028_CR50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ana.25900","volume":"88","author":"G Coratti","year":"2020","unstructured":"Coratti G, Messina S, Lucibello S et al (2020) Clinical variability in spinal muscular atrophy type III. Ann Neurol 88(6):1109\u20131117. https:\/\/doi.org\/10.1002\/ana.25900","journal-title":"Ann Neurol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-022-02028-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-022-02028-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-022-02028-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T15:30:57Z","timestamp":1727623857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-022-02028-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2028"],"URL":"https:\/\/doi.org\/10.1007\/s13760-022-02028-6","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no competing interests for any author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript presents a systematic review and does not contain original patient data. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}